Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 16/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 14/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14739454 | 1.00 | ROCK1 (1.00) | ROCK1ROCK2MAPTMEN1ALDH1A1 | |
| SCHEMBL14739254 | 1.00 | ROCK1 (1.00) | ROCK1ROCK2MAPTMEN1ALDH1A1 | |
| SCHEMBL14739248 | 0.87 | ROCK1 (1.00) | ROCK1ROCK2MAPTALDH1A1MAPK1 | |
| SCHEMBL14739803 | 0.87 | ROCK1 (1.00) | ROCK1ROCK2MAPTALDH1A1MAPK1 | |
| SCHEMBL2557455 | 0.87 | ROCK1 (1.00) | ROCK1ROCK2MAPTALDH1A1MAPK1 | |
| SCHEMBL2556165 | 0.86 | ROCK2 (1.00) | ROCK1ROCK2 | |
| SCHEMBL2560272 | 0.86 | ROCK2 (1.00) | ROCK1ROCK2 | |
| SCHEMBL14738809 | 0.86 | ROCK2 (1.00) | ROCK1ROCK2 | |
| SCHEMBL10814398 | 0.82 | MEN1 (0.83) | ROCK1ROCK2MAPTMEN1ALDH1A1 | |
| SCHEMBL1881014 | 0.80 | ADORA3 (0.82) | ROCK1ROCK2MAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011130740-A2 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | ROCK1 1/4885ROCK2 2/4885MAPT 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.